JUN 20, 2018 6:23 AM PDT

New Drug 'Moxidectin' for River Blindness

WRITTEN BY: Nouran Amin

A new treatment to help eliminate a neglected tropical disease was developed thanks in part to an incentive program devised by researchers at Duke University.

Moxidectin, a macrocyclic lactone created by the drug company Medicines Development for Global Health, was recently approved by The U.S. Food and Drug Administration.

Moxidectin seeks to treat helminthic infections that affect more than 15 million people worldwide. The firm will be awarded a voucher for priority review of another drug, under a system first proposed by David Ridley, a professor at Duke University’s Fuqua School of Business, Henry Grabowski of the Duke Department of Economics, and Jeffrey Moe, of the Duke Global Health Institute.

“With a new treatment, we’re one step closer to eliminating river blindness,” Ridley said. “And the developer is a non-profit company,” explains David Ridley, a professor at Duke University’s Fuqua School of Business.

River blindness, or onchocerciasis, is typically found in economically-distressed areas in sub-Saharan Africa. The clinical trials published in The Lancet medical journal found that moxidectin to be more effective in treating river disease than any current treatment.

Moxidectin is a anthelmintic medicine that targets the parasite's glutamate-gated chloride ion channels. These ion channels are crucial to the function of invertebrate nerve and muscle cells. Moxidectin has activity against O. volvulus microfilariae, the parasite involved in river blindness disease, but does not have an effect on adult O. volvulus parasites.

 

Individuals with river blindness administered moxidectin had adverse events consistent with those associated with efficacy. The nature and severity of these effects from moxidectin recipients were similar to another drug known as ivermectin.

 

Eosinophilia, pruritus, musculoskeletal pain, headache, lymphopenia, tachycardia, rash, abdominal pain, hypotension, pyrexia, leukocytosis, influenza-like illness, neutropenia, cough, lymph node pain, dizziness, diarrhea, hyponatremia and peripheral swelling; were are all considered to be the most common adverse reactions.

 

However, the efficacy of repeat administrations of moxidectin have yet to be examined. Moxidectin is given as 2 mg tablets for administration as an 8 mg dose per oral to patients at least 12 years of age with O. volvulus infection.

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 12, 2021
Drug Discovery & Development
Epidural Use Not Linked To Autism
APR 12, 2021
Epidural Use Not Linked To Autism
Epidurals are a form of pain relief during childbirth and is used by more than half of all women in labor. Many women wh ...
MAY 06, 2021
Cannabis Sciences
New CBD Analog Outperforms Regular CBD for Pain Relief
MAY 06, 2021
New CBD Analog Outperforms Regular CBD for Pain Relief
Researchers from Temple University Health System have found that a novel cannabidiol (CBD) analog can reverse pain sensi ...
MAY 14, 2021
Health & Medicine
A National Standard THC Dose for Researchers is Here
MAY 14, 2021
A National Standard THC Dose for Researchers is Here
    Whatever your stance on cannabis, almost  everyone would agree that more, better quality, research sh ...
JUN 03, 2021
Drug Discovery & Development
Antibiotics Ineffective Against Lung-Scarring Disease
JUN 03, 2021
Antibiotics Ineffective Against Lung-Scarring Disease
Researchers behind a large trial of antibiotics for chronic lung diseases have found that that the drugs are ineffective ...
JUN 10, 2021
Plants & Animals
Antibiotics Fight Mysterious Coral Disease
JUN 10, 2021
Antibiotics Fight Mysterious Coral Disease
Coral reefs besieged by climate change and pollutants have a new line of defense against disease-an antibiotic commonly ...
JUN 14, 2021
Microbiology
Researchers Identify a Novel, Beneficial Bacterium
JUN 14, 2021
Researchers Identify a Novel, Beneficial Bacterium
Since researchers were able to use genetic technologies to reveal how important the gut microbiome is to human health, t ...
Loading Comments...